RT info:eu-repo/semantics/article
T1 ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patients
A1 Vargas, Teodoro
A1 Moreno Rubio, Juan
A1 Herranz, Jesús
A1 Cejas, Paloma
A1 Molina, Susana
A1 González-Vallinas Garrachón, Margarita
A1 Mendiola, Marta
A1 Burgos, Emilio
A1 Aguayo, Cristina
A1 Custodio, Ana B.
A1 Machado, Isidro
A1 Ramos, David
A1 Gironella, Meritxell
A1 Espinosa Salinas, Isabel
A1 Ramos, Ricardo
A1 Martín Hernández, Roberto
A1 Risueño, Alberto
A1 Rivas, Javier de las
A1 Reglero, Guillermo
A1 Yaya, Ricardo
A1 Fernández Martos, Carlos
A1 Aparicio, Jorge
A1 Maurel, Joan
A1 Feliu, Jaime
A1 Ramírez de Molina, Ana
K1 Cáncer de colon
K1 Carcinogénesis
K1 3207.13 Oncología
AB Lipid metabolism plays an essential role in carcinogenesis due to the requirementsof tumoral cells to sustain increased structural, energetic and biosynthetic precursordemands for cell proliferation. We investigated the association between expressionof lipid metabolism-related genes and clinical outcome in intermediate-stage coloncancer patients with the aim of identifying a metabolic profile associated with greatermalignancy and increased risk of relapse. Expression profile of 70 lipid metabolismrelated genes was determined in 77 patients with stage II colon cancer. Cox regressionanalyses using c-index methodology was applied to identify a metabolic-relatedsignature associated to prognosis. The metabolic signature was further confirmed intwo independent validation sets of 120 patients and additionally, in a group of 264patients from a public database. The combined analysis of these 4 genes, ABCA1,ACSL1, AGPAT1 and SCD, constitutes a metabolic-signature (ColoLipidGene) able toaccurately stratify stage II colon cancer patients with 5-fold higher risk of relapse withstrong statistical power in the four independent groups of patients. The identification www.impactjournals.com/oncotarget 7349 Oncotargetof a group of 4 genes that predict survival in intermediate-stage colon cancer patientsallows delineation of a high-risk group that may benefit from adjuvant therapy, andavoids the toxic and unnecessary chemotherapy in patients classified as low-risk group.
PB Impact Journals
SN 1949-2553
YR 2015
FD 2015
LK http://uvadoc.uva.es/handle/10324/42588
UL http://uvadoc.uva.es/handle/10324/42588
LA eng
NO Oncotarget, 2015, vol. 6, n. 9, p. 7348-7363
NO Producción Científica
DS UVaDOC
RD 24-nov-2024